JimJimJimJim Posted August 23, 2013 Share Posted August 23, 2013 Jim Marshall (not a doctor) said ... Hot flashes (or hot flushes) can become such a nuisance to some men on hormone therapy (ADT) that your doctor may recommend drug treatment. One drug sometimes prescribed is Gabapentin at a low dose. The study reported below was done to find the lowest dose that would be effective. This was necessary because the drug does slow nerve response while you take it, and at higher doses (used to treat epilepsy) it can have side effects which may effect daily life. The safe dose was found to be 300 mg per day. The full article is to be found at: full article: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3075822/ where it qualifies the 'suggest' in the abstract. ... end Jim J Support Oncol. 2010 May-Jun;8(3):128-32. Gabapentin for the management of hot flashes in prostate cancer survivors: a longitudinal continuation Study-NCCTG Trial N00CB. Moraska AR, Atherton PJ, Szydlo DW, Barton DL, Stella PJ, Rowland KM Jr, Schaefer PL, Krook J, Bearden JD, Loprinzi CL. Source Mayo Clinic Rochester, Rochester, Minnesota 55905, USA. Abstract Hot flashes are a complication of androgen deprivation therapy for prostate cancer. A phase III study showed that use of low-dose gabapentin was well tolerated and moderately decreased the frequency of hot flashes due to androgen deprivation therapy when taken for 4 weeks. The current study, an open-label continuation of the randomized study, examined the efficacy and toxicity of gabapentin when taken for (an additional) 8 weeks. Patients were allowed to start, or continue, gabapentin and to titrate the dose to maximum efficacy, up to 900 mg/d. They were asked to complete a hot flash diary daily and keep weekly logs of toxicity, satisfaction with hot flash control, and quality of life. The moderate reduction in hot flash frequency and severity in the randomized phase of the study appeared to be maintained during this continuation phase. Men originally receiving the placebo or lowest dose of gabapentin (300 mg/d) had improved hot flash control relative to that at the end of the randomized phase. Minimal adverse effects were reported. These findings suggest that low-dose gabapentin is moderately efficacious for at least 12 weeks of hot flash treatment in men undergoing androgen deprivation therapy for prostate cancer and seems to be well tolerated. (NCT00028572) PMID: 2055292 Link to comment Share on other sites More sharing options...
This topic is now archived and is closed to further replies.